A Real-World Efficacy and Safety of KEYNOTE-522 Regimen in Patients With Early Triple-Negative Breast Cancer - PubMed
18 hours ago
- #pathologic complete response
- #pembrolizumab
- #triple-negative breast cancer
- The real-world study evaluated the KEYNOTE-522 regimen (neoadjuvant pembrolizumab plus chemotherapy) in 174 Korean patients with early-stage triple-negative breast cancer (TNBC).
- The overall pathologic complete response (pCR) rate was 62.1%, with high baseline Ki-67 expression (≥75%) significantly associated with achieving pCR (odds ratio, 2.84; p=0.002).
- The 12-month event-free survival (EFS) rate was 97.4%, significantly higher in patients who achieved pCR compared to those who did not (100% vs. 93.1%, p=0.007).
- The treatment completion rate was 92.0%, and immune-related adverse events occurred in 13.8% of patients, indicating manageable toxicity.